System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Letter Ahead of print

PubMed: 42839068 DOI: 10.1038/s41375-026-03162-3

Measurable residual disease-guided, fixed-duration, potentially definitive therapy for standard risk newly diagnosed multiple myeloma.

Leukemia

Authors: Bhagirathbhai R Dholaria, Eva Medvedova, Gayathri Ravi, Binod Dhakal, Natalie S Callander, Kelly N Godby, Susan Bal, Timothy Schmidt, Rebecca W Silbermann, Luciano J Costa

Affiliations

  • Division of Hematology Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Division of Hematology/Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
  • Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA.
  • Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
  • Division of Hematology, Medical Oncology and Palliative Care, Department of Medicine, University of Wisconsin, Madison, WI, USA.
  • Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA.

MeSH

Leukemia, Multiple Myeloma, Therapeutics